Overall, as illustrated in the schematic diagram (Figure 6C), this study first demonstrated that ginsenoside Rb1 ameliorates CKD‐associated VC by inhibiting the Wnt/β‐catenin pathway by activating PPAR‐γ. Here, PPARG is linked to chronic kidney disease.